The role of beclin-1 expression in patients with gastric cancer: a meta-analysis

Beclin-1 has been identified as a reliable biomarker in monitoring the prognosis for tumors. We carried out a meta-analysis focusing on the relationship between beclin-1 and the clinical characteristics of patients with gastric cancer. We identified articles in MEDLINE, PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure databases by using the following strategy: (“beclin 1” or “beclin-1” or “ATG6”) and (“gastric cancer” or “stomach cancer”). We conducted a final analysis of 1,254 patients from seven studies. The pooled odds ratio (OR) indicated a significant association between beclin-1 expression and the differentiation of gastric cancer (pooled OR = 0.23; 95 % confidence interval (CI) = 0.07–0.73) or tumor–node–metastasis staging of gastric cancer (pooled OR = 0.62; 95 % CI = 0.48–0.79). Beclin-1 expression was different in intestinal- and diffuse-type gastric cancer (pooled OR = 0.55; 95 % CI = 0.39–0.77). No association between beclin-1 and tumor size (pooled OR = 0.73; 95 % CI = 0.45–1.17) or lymph node metastasis (pooled OR = 0.59; 95 % CI = 0.17–1.99) was observed.